Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509

CAS  PubMed  Google Scholar 

Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) All departments of rheumatology in denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62(1):22–32

CAS  PubMed  Google Scholar 

Torrente-Segarra V, Urruticoechea Arana A, Sánchez-Andrade Fernández A, Tovar Beltrán JV, Muñoz Jiménez A et al (2015) (RENACER StudyGroup). RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database. Mod Rheumatol 7:1–6

Google Scholar 

Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas JR, Pato E et al (2016) Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol 45:456–460

CAS  PubMed  Google Scholar 

Finckh A, Simard JF, Gabay C, Guerne PA (2006) SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65:746–752

CAS  PubMed  Google Scholar 

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J et al (2011) Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry. J Rheumatol 38:1273–1281

CAS  PubMed  Google Scholar 

Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F et al (2009) TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 1173:837–846

CAS  PubMed  Google Scholar 

Bergstra SA, Machado PM, van den Berg R, Landewé RB, Huizinga TW. Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives. Clin Exp Rheumatol. 2016;34:S87-S90

Frisell T, Baecklund E, Bengtsson K, Di Giuseppe D, Forsblad-d’Elia H, Askling J, ARTIS Study group (2018) Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics. Ann Rheum Dis 77:650–657

CAS  PubMed  Google Scholar 

Scirè CA, Caporali R, Sarzi-Puttini P, Frediani B, Di Franco M, Tincani A et al (2013) Monitornet project. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. Clin Exp Rheumatol 31:857–863

PubMed  Google Scholar 

Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, ARTIS Study Group et al (2015) Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and Infliximab. Ann Rheum Dis 74:354–360

CAS  PubMed  Google Scholar 

Gabay C, Riek M, Scherer A, Finckh A (2015) SCQM collaborating physicians. Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss clinical quality management registry. Rheumatology (Oxford) 54:1664–1672

CAS  PubMed  Google Scholar 

Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP et al (2017) British society for rheumatology biologics register. Use and effectiveness of Tocilizumab among patients with rheumatoid arthritis: an observational study from the British society for rheumatology biologics register for rheumatoid arthritis. Clin Rheumatol 36:241–250

PubMed  Google Scholar 

Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordström DC et al (2020) Comparative effectiveness of TNF inhibitors and Tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis. Semin Arthritis Rheum 50:17–24

CAS  PubMed  Google Scholar 

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK et al (2018) Comparative effectiveness of Tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration. Ann Rheum Dis 77:1276–1282

CAS  PubMed  Google Scholar 

Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK et al (2019) Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology (Oxford). 1;58:2221–2229

Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM (2017) Treatment of rheumatoid arthritis with Anti-Tumor necrosis factor or Tocilizumab therapy as first biologic agent in a global comparative observational study. Arthritis Care Res (Hoboken) 69:1484–1494

CAS  PubMed  Google Scholar 

Emery P, Vlahos B, Szczypa P, Thakur M, Jones HE, Woolcott J et al (2020) Long-term drug survival of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 47:493–501

CAS  PubMed  Google Scholar